Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07318805 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
A Phase 1 study of Colorectal Cancer and Triple Negative Breast Cancer, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 260
- Enrollment target
- 3
- Study locations
NCT07318805 is a Phase 1 study of Colorectal Cancer and Triple Negative Breast Cancer that is actively recruiting participants, run by Pfizer. The registered enrollment target is 260 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07318805, a Phase 1 study of Colorectal Cancer and Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 260 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This study is seeking participants that have advanced or metastatic breast cancer (BC), or advanced or metastatic colorectal cancer (CRC). All participants in this study will take the study medication (PF-08032562) as pill by mouth. This will be repeated for 28-day cycles. Depending on which part of the study participants are enrolled into, they will receive the study medication PF-08032562 alone or in combination with other anti-cancer medications. The study medication (PF-08032562) will be taken by mouth (PO) in combination with other anti-cancer medications given in the study clinic by intramuscular (IM) injection into the muscle or intravenous (IV) infusion that is directly injected into the veins at different times (depending on the treatment) during the 28-day cycle. The study may also test different schedules.
Conditions Studied
Interventions
- DRUG Fluorouracil
- DRUG Oxaliplatin
- DRUG Cetuximab
- DRUG Fulvestrant
- DRUG PF-08032562
Study Locations (3)
Michigan
- START Midwest, LLC - Grand Rapids
Texas
- START San Antonio - San Antonio
Utah
- START Mountain Region - West Valley City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2030-04-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07318805
The ClinicalTrials.gov registry entry for NCT07318805 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (83% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Fluorouracil is the first listed.
NCT07318805 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Michigan, Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT07318805 about?
NCT07318805 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors". The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This stu...
What is the current status of trial NCT07318805?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2025-12-16. Estimated completion is 2030-04-14.
What conditions does trial NCT07318805 study?
This clinical trial studies the following conditions: Colorectal Cancer, Triple Negative Breast Cancer, Advanced Breast Cancer, Metastatic Colorectal Adenocarcinoma, Metastatic Breast Cancer (HR+/ HER2-).
What interventions are being tested in trial NCT07318805?
The interventions under investigation include: Fluorouracil (DRUG), Oxaliplatin (DRUG), Cetuximab (DRUG), Fulvestrant (DRUG), PF-08032562 (DRUG).
Who is sponsoring clinical trial NCT07318805?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07318805 being conducted?
This trial has 3 study locations across Michigan, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.